Holen Sie sich die Stockscreener-App
1.44
5.11%
0.07
Handel nachbörslich:
1.46
0.02
+1.39%
Schlusskurs vom Vortag:
$1.37
Offen:
$1.41
24-Stunden-Volumen:
54,431
Relative Volume:
0.20
Marktkapitalisierung:
$54.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.82M
KGV:
-4.80
EPS:
-0.3
Netto-Cashflow:
$-18.01M
1W Leistung:
-7.69%
1M Leistung:
-27.64%
6M Leistung:
+63.32%
1J Leistung:
+21.01%
1-Tages-Spanne:
$1.35
$1.53
1-Wochen-Bereich:
$1.19
$1.54
52-Wochen-Spanne:
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Vergleichen Sie ESLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.44 | 51.74M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Signs Multiple Material Agreements - TradingView — Track All Markets
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - The AI Journal
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Files for Secondary Offering - marketscreener.com
Investment Review: How interest rate cuts could boost Estrella Immunopharma Inc. stock2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Why Estrella Immunopharma Inc. stock remains on buy listsVolume Spike & Free Technical Pattern Based Buy Signals - Улправда
Is Estrella Immunopharma Inc. stock affected by interest rate hikes - Улправда
Is Estrella Immunopharma Inc. stock a safe haven assetEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Published on: 2025-12-20 01:59:16 - Улправда
Insider Buy: Is Estrella Immunopharma Inc. stock a safe haven asset2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipJuly 2025 WrapUp & High Accuracy Swing Trade Signals - DonanımHaber
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% HigherHere's Why - MarketBeat
Levels Update: How interest rate cuts could boost Estrella Immunopharma Inc. stockWeekly Stock Recap & Verified Swing Trading Watchlists - ulpravda.ru
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):